Cargando…
Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study
PURPOSE: To evaluate factors influencing the insulin and levothyroxine requirement in patients with autoimmune polyglandular syndrome type 3 (APS-3) vs. patients with type 1 diabetes mellitus (T1DM) and autoimmune hypothyroidism (AH) alone, respectively. METHODS: Fifty patients with APS-3, 60 patien...
Autores principales: | Guarnotta, V., Pillitteri, G., Gambino, G., Radellini, S., Vigneri, E., Pizzolanti, G., Giordano, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195810/ https://www.ncbi.nlm.nih.gov/pubmed/33099763 http://dx.doi.org/10.1007/s40618-020-01421-3 |
Ejemplares similares
-
Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis
por: Guarnotta, Valentina, et al.
Publicado: (2018) -
Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability
por: Guarnotta, Valentina, et al.
Publicado: (2018) -
Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study
por: Guarnotta, Valentina, et al.
Publicado: (2019) -
One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021) -
Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021)